Larimar Therapeutics, Inc. (LRMR)

$2.72

+0.04 (+1.49%)
Rating:
Recommendation:
-
Symbol LRMR
Price $2.72
Beta 0.823
Volume Avg. 0.05M
Market Cap 48.172M
Shares () -
52 Week Range 2.4-15.258
1y Target Est -
DCF Unlevered LRMR DCF ->
DCF Levered LRMR LDCF ->
ROE -72.75% Strong Sell
ROA -66.68% Strong Sell
Operating Margin -
Debt / Equity 24.72% Neutral
P/E -
P/B 0.87 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LRMR news


Dr. Carole S. Ben-Maimon
Healthcare
Biotechnology
NASDAQ Global Market

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.